News for Terumo Corporation (4543N.MX)

\n\nPR NewswireLAKEWOOD, Colo., April 16, 2025\n\n\n\nDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite b

\n Patrick Daly appointed as Chief Business Officer at Terumo Blood and Cell Technologies (Terumo BCT). Daly brings over 30 years of experience in the heal

Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth

\n Terumo Health Outcomes launches FDA-cleared Medis QFR 3.0 software in the U.S. for coronary physiology assessment. The software is integrated with THO's

Operator: Good morning and thank you for standing by. Currently, all the participants are in a listen-only mode. After management's discussion, there will be a question and answer session.

PR NewswireALISO VIEJO, Calif., March 19, 2025 More than 25,000 Devices Implanted Worldwide from 2010-20251ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/

PR NewswireCAESAREA, Israel, March 10, 2025 Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® user

Terumo Corporation (OTCPK:TRUMF) Q3 2025 Earnings Conference Call February 13, 2025 3:00 AM ETCompany ParticipantsJin Hagimoto – Chief Financial...

The following slide deck was published by Terumo Corporation in conjunction with their 2025 Q3 earnings call.

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense ® Sales for 2024 in North America

Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter

PR NewswireCAESAREA, Israel, Nov. 26, 2024 FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025Conference call to

PR NewswireCAESAREA, Israel, Nov. 25, 2024 Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablationC

PR NewswireLAKEWOOD, Colo., Nov. 21, 2024 Recent peer-reviewed study supports what patients shared with their own voices: Automated red blood cell exchange

The Blood Glucose Monitoring Market Size sector reached a market value of USD 16.46 Billion in 2023. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 6.2% from…

Terumo Corporation (OTCPK:TRUMF) Q2 2025 Earnings Conference Call November 7, 2024 3:00 AM ETCompany ParticipantsJin Hagimoto – Chief Financial...

The Perfusion Systems Market Size sector reached a market value of USD 4.62 billion in 2023. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 11% from 2023 to…

The following slide deck was published by Terumo Corporation in conjunction with their 2025 Q2 earnings call.

The syringes market is expected to exceed USD 24,101 million in 2024. The market is expected to exceed USD 56,694.2 million by 2033, with a robust CAGR of...